Bristol-Myers Squibb Company (BMY)

Market Cap	119.40B
Revenue (ttm)	47.44B
Net Income (ttm)	-7.26B
Shares Out	2.03B
EPS (ttm)	-3.58
PE Ratio	n/a
Forward PE	8.33
Dividend	$2.40 (4.08%)
Ex-Dividend Date	Oct 4, 2024

Volume	7,369,047
Open	58.35
Previous Close	58.23
Day's Range	57.62 - 58.92
52-Week Range	39.35 - 61.08
Beta	0.44
Analysts	Hold
Price Target	53.92 (-8.41%)
Earnings Date	Oct 31, 2024

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1887
• Employees: 34,100
• Stock Exchange: NYSE
• Ticker Symbol: BMY
• Website: https://www.bms.com

Financial Performance

In 2023, BMY's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.

Analyst Forecast

According to 14 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $53.92, which is a decrease of -8.41% from the latest price.

Price Target

$53.92

(-8.41% downside)

Analyst Consensus: Hold